Allogene Therapeutics, Inc. Proceeds from Common Stock Issued
Allogene Therapeutics, Inc. (ALLO) reported Proceeds from Common Stock Issued of $10.00 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-05-13
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $10.00M.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $0.00.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2023-09-30 was $3.19M.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2023 was $91.11M.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $0.00.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Allogene Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $595.73M.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-03-31 | $10.00M 10-Q · filed 2025-05-13 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $3.19M derived: sum of 3 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.19M derived: sum of 2 quarters · filed 2024-03-14 | $91.11M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $91.11M 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $87.92M 10-Q · filed 2023-08-02 | |||||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K/A · filed 2024-03-14 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | |||||
| 2021-12-31 | $0.00 10-K/A · filed 2024-03-14 | |||||
| 2020-12-31 | $595.73M 10-K/A · filed 2024-03-14 | $621.93M 10-K · filed 2021-02-25 | ||||
| 2020-03-31 | $14.85M 10-Q · filed 2020-05-06 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-23 | $54.22M 10-K · filed 2020-02-27 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 | |||||
| 2018-12-31 | $343.69M 10-K · filed 2021-02-25 | |||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |